MedPath

Research to Evaluate a Possible Relation Between Values Obtained After Processing CT Images, Lung Function Tests and the Experience of the Patient During an Exacerbation in COPD Patients.

Not Applicable
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Radiation: Functional Respiratory Imaging
Registration Number
NCT01684384
Lead Sponsor
FLUIDDA nv
Brief Summary

In this study the consequences of exacerbations will be visualized by high resolution computed tomography (HRCT) scan at functional residual capacity (FRC) and total lung capacity (TLC) as taken during an episode of exacerbation and after recovering. Changes in HRCT based airway dimensions and computational fluid dynamic (CFD) -based resistance values will be correlated with changes in patient reported outcomes (PROs) and lung function tests recorded at the same time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
53
Inclusion Criteria
  • Male or female, ≥ 40 years old
  • COPD as defined by the global Initiative on obstructive lung disease4
  • Post-bronchodilator FEV1/FVC < 70% AND post-bronchodilator FEV1 <80%pred as documented in the last 5 years.
  • Smoking history of at least 10 pack-years
  • At entry in the study experiencing an exacerbation defined as an acute change in the patient 's baseline dyspnea, cough, and/or sputum that is beyond normal day to day variations, and that necessitates the administration or doubling of systemic corticosteroid treatment.
  • Patients must be able to understand and complete protocol requirements, instructions, questionnaires and protocol-stated restrictions.
  • Written and signed informed consent
Exclusion Criteria
  • Pregnant or lactating females
  • Patient diagnosed with asthma
  • Patient with pneumonia as defined radiologically at the start of the exacerbation
  • Patient with a history of or presence of lung cancer
  • Patient with an indication for non-invasive ventilation
  • Patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
  • Patient who received any investigational new drug within the last 4 weeks prior to visit 1.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
No treatmentFunctional Respiratory ImagingCT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
Primary Outcome Measures
NameTimeMethod
Changes in lung function parametersBaseline (= during exacerbation) and after about 6 weeks (= after recovering)

The primary objective of this study is to evaluate whether changes in HRCT based airway dimensions and Computational Fluid Dynamic (CFD)-based resistance values correlate with changes in lung function parameters, under the conditions of exacerbation of COPD as well as after recovering from exacerbation.

Changes in functional respiratory imaging parametersBaseline (= during exacerbation) and after about 6 weeks (= after recovering)

The primary objective of this study is to evaluate whether changes in HRCT based airway dimensions and Computational Fluid Dynamic (CFD)-based resistance values correlate with changes in lung function parameters, under the conditions of exacerbation of COPD as well as after recovering from exacerbation.

Secondary Outcome Measures
NameTimeMethod
Changes in patient reported outcome (PRO) measuresBaseline (= during exacerbation) and after about 6 weeks (= after recovering)

The secondary objective is to check if the changes in CFD data actually correlate better with changes in PRO than changes in lung function parameters.

Trial Locations

Locations (4)

Antwerp University Hospital

🇧🇪

Edegem, Antwerp, Belgium

University of Florence

🇮🇹

Florence, Italy

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

Maastricht University Medical Center

🇳🇱

Maastricht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath